Product Description
HZN-457 is a small interfering RNA (siRNA) medicine candidate conjugated to N-acetylgalactosamine (GalNAc) that selectively targets and silences xanthine dehydrogenase expression in the liver, which produces uric acid. The development of HZN-457 is through an exclusive collaboration between Horizon and Arrowhead Pharmaceuticals, Inc. (Sourced from: https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-first-subject-dosed-phase-1)
Mechanisms of Action: XDH Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: New Zealand
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Gout
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05565768 |
HZNP-HZN-457-101 | P1 |
Completed |
Gout |
2023-08-09 |
69% |
2023-09-08 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/06/2024 |
News Article |
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results |
|
03/01/2023 |
News Article |
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results |
|
02/06/2023 |
News Article |
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results |
|
12/08/2022 |
News Article |
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout |